journal
https://read.qxmd.com/read/37728940/treatment-patterns-for-alopecia-areata-in-the-us
#1
JOURNAL ARTICLE
Hemin Lee, Kathie P Huang, Arash Mostaghimi, Niteesh K Choudhry
IMPORTANCE: Alopecia areata (AA) is characterized by hair loss ranging from patches of hair loss to more extensive forms, including alopecia totalis (AT) and alopecia universalis (AU). There is a lack of consensus for treatment. Understanding current practice patterns could help the identification of treatment needs and development of standards of care. OBJECTIVE: To review treatment patterns for adults with AA in the US between 2015 and 2020. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used medicine and pharmacy claims for commercially insured individuals from the IBM MarketScan Research Database to assess adults (≥18 years) newly treated for AA between October 15, 2015, and February 28, 2020...
September 20, 2023: JAMA Dermatology
https://read.qxmd.com/read/37728937/pain-as-a-patient-reported-outcome-measure-in-pyoderma-gangrenosum
#2
JOURNAL ARTICLE
Katherine M Erickson, Shannon Kody, Alex G Ortega-Loayza
No abstract text is available yet for this article.
September 20, 2023: JAMA Dermatology
https://read.qxmd.com/read/37728935/bullous-aplasia-cutis-as-a-presenting-sign-of-encephalocele
#3
JOURNAL ARTICLE
Jenna Borok, Annette M Wagner, Anthony J Mancini
No abstract text is available yet for this article.
September 20, 2023: JAMA Dermatology
https://read.qxmd.com/read/37728912/treatment-of-hydroxyurea-induced-ulcers-with-timolol
#4
JOURNAL ARTICLE
Angelina S Hwang, Elika Hoss, Mark R Pittelkow, Yul W Yang
No abstract text is available yet for this article.
September 20, 2023: JAMA Dermatology
https://read.qxmd.com/read/37728897/patient-perspectives-on-living-with-severe-prurigo-nodularis
#5
JOURNAL ARTICLE
Danielle Rodriguez, Shawn G Kwatra, Carla Dias-Barbosa, Fanyang Zeng, Zarif K Jabbar Lopez, Christophe Piketty, Jorge Puelles
IMPORTANCE: Because of a paucity of qualitative research on prurigo nodularis (PN), the symptoms and impacts of PN that are most important to patients are poorly understood. OBJECTIVE: To explore patients' perspectives on their PN symptoms and to understand the impacts of the condition. DESIGN, SETTING, AND PARTICIPANTS: One-on-one qualitative telephone interviews were held with English-speaking US adults aged 18 years or older with a confirmed diagnosis of PN, severe pruritus, and moderate to severe sleep disturbance...
September 20, 2023: JAMA Dermatology
https://read.qxmd.com/read/37728895/clinical-management-of-neuropathic-itch
#6
JOURNAL ARTICLE
Kelsey L Auyeung, Blair A Jenkins, Brian S Kim
No abstract text is available yet for this article.
September 20, 2023: JAMA Dermatology
https://read.qxmd.com/read/37703033/elucidation-of-pain-mechanisms-in-hidradenitis-suppurativa
#7
JOURNAL ARTICLE
Sarah K Whitley
No abstract text is available yet for this article.
September 13, 2023: JAMA Dermatology
https://read.qxmd.com/read/37703032/cutaneous-vascular-malformations-in-a-53-year-old-woman-with-neurologic-symptoms
#8
JOURNAL ARTICLE
Jonas Rauterberg, Julia Schreml, Iliana Tantcheva-Poór
No abstract text is available yet for this article.
September 13, 2023: JAMA Dermatology
https://read.qxmd.com/read/37703028/error-in-author-affiliation
#9
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 13, 2023: JAMA Dermatology
https://read.qxmd.com/read/37703005/risk-of-multiple-primary-cancers-in-patients-with-merkel-cell-carcinoma-a-seer-based-analysis
#10
JOURNAL ARTICLE
Edward Eid, Nolan J Maloney, Zhuo Ran Cai, Lisa C Zaba, Nour Kibbi, Esther M John, Eleni Linos
IMPORTANCE: The risk of subsequent primary cancers after a diagnosis of cutaneous Merkel cell carcinoma (MCC) is not well established. OBJECTIVE: To evaluate the risk of subsequent primary cancers after the diagnosis of a first primary cutaneous MCC. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed data from 17 registries of the Surveillance, Epidemiology, and End Results (SEER) Program from January 1, 2000, to December 31, 2019...
September 13, 2023: JAMA Dermatology
https://read.qxmd.com/read/37703003/skin-related-quality-of-life-during-autoimmune-bullous-disease-course
#11
JOURNAL ARTICLE
Zachary H Hopkins, Amber Jimenez, Vanina L Taliercio, Jennie T Clarke, Christopher B Hansen, Christopher M Hull, Jamie L W Rhoads, John J Zone, Vikram N Sahni, Jacob Kean, Aaron M Secrest
IMPORTANCE: Autoimmune bullous diseases (AIBDs) are chronic relapsing-remitting conditions with significant morbidity. Skin-related quality of life (SRQL) may vary by AIBD subtype and disease type. Disease severity and flare severity can be difficult to define; SRQL can offer a key insight. OBJECTIVES: To investigate the Skindex-16 score as an SRQL measure in AIBD subtypes during flare and nonflare states and to evaluate Skindex-16 construct validity. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study was conducted from September 1, 2016, to February 1, 2020, among 192 patients at the University of Utah Health autoimmune dermatology clinic with pemphigoid, pemphigus, dermatitis herpetiformis, and linear immunoglobulin A disease...
September 13, 2023: JAMA Dermatology
https://read.qxmd.com/read/37702999/quantitative-sensory-testing-to-characterize-sensory-changes-in-hidradenitis-suppurativa-skin-lesions
#12
JOURNAL ARTICLE
Ali Alsouhibani, Patrick Speck, Emily F Cole, Danielle E Mustin, Yiwen Li, Jason R Barron, Lauren A V Orenstein, Daniel E Harper
IMPORTANCE: Pain is the most impactful symptom in patients with hidradenitis suppurativa (HS). Characterization of sensory profiles may improve understanding of pain mechanisms in HS and facilitate identification of effective pain management strategies. OBJECTIVE: To characterize somatosensory profiles in patients with HS at clinically affected and nonaffected sites compared with pain-free reference data. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was conducted at the Emory University Dermatology Clinic...
September 13, 2023: JAMA Dermatology
https://read.qxmd.com/read/37672282/changes-in-health-care-costs-survival-and-time-toxicity-in-the-era-of-immunotherapy-and-targeted-systemic-therapy-for-melanoma
#13
JOURNAL ARTICLE
Sarah B Bateni, Paul Nguyen, Antoine Eskander, Soo Jin Seung, Nicole Mittmann, Matthew Jalink, Arjun Gupta, Kelvin K W Chan, Nicole J Look Hong, Timothy P Hanna
IMPORTANCE: Melanoma treatment has evolved during the past decade with the adoption of adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on health care costs and outcomes in routine practice. OBJECTIVE: To examine changes in health care costs, overall survival (OS), and time toxicity associated with primary treatment of melanoma. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed a longitudinal, propensity score (PS)-matched, retrospective cohort of residents of Ontario, Canada, aged 20 years or older with stages II to IV cutaneous melanoma identified from the Ontario Cancer Registry from January 1, 2018, to March 31, 2019...
September 6, 2023: JAMA Dermatology
https://read.qxmd.com/read/37672263/incidence-of-in-situ-and-invasive-cutaneous-melanomas-during-the-covid-19-pandemic-in-the-us
#14
JOURNAL ARTICLE
Daniel Y Kim, Rebecca I Hartman
No abstract text is available yet for this article.
September 6, 2023: JAMA Dermatology
https://read.qxmd.com/read/37672258/acquired-melanocytic-nevi-mimicking-acral-lentiginous-melanoma-in-a-patient-taking-a-braf-inhibitor
#15
JOURNAL ARTICLE
Zaeem H Nazir, Helen C Haliasos, Klaus J Busam, Michael A Marchetti, Konstantinos Linos, Ashfaq A Marghoob
No abstract text is available yet for this article.
September 6, 2023: JAMA Dermatology
https://read.qxmd.com/read/37672255/cutaneous-adverse-events-and-cancer-survival-prognosis-with-immune-checkpoint-inhibitor-treatment-a-systematic-review-and-meta-analysis
#16
JOURNAL ARTICLE
Yaxin Du, Wenjie Wu, Mei Chen, Zhengbang Dong, Fei Wang
IMPORTANCE: Growing research suggests that the prevalence of cutaneous immune-related adverse events (cirAEs) is associated with favorable outcomes among individuals with cancer who receive immune checkpoint inhibitor (ICI) treatment. OBJECTIVE: To identify whether the presence of cirAEs and their subtypes subsequent to ICI administration is associated with enhanced cancer prognosis. DATA SOURCES: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for publications examining the association between cirAE development during ICI treatment and subsequent cancer prognosis...
September 6, 2023: JAMA Dermatology
https://read.qxmd.com/read/37650576/stage-specific-risk-of-recurrence-and-death-from-melanoma-in-denmark-2008-2021-a-national-observational-cohort-study-of-25%C3%A2-720-patients-with-stage-ia-to-iv-melanoma
#17
JOURNAL ARTICLE
Neel M Helvind, Marie Brinch-Møller Weitemeyer, Annette H Chakera, Helle W Hendel, Eva Ellebæk, Inge Marie Svane, Mette W Kjærskov, Sophie Bojesen, Helle Skyum, Søren K Petersen, Lars Bastholt, Christoffer Johansen, Pernille E Bidstrup, Lisbet R Hölmich
IMPORTANCE: To ensure optimal treatment and surveillance of patients with melanoma, knowledge of the clinical stage-specific risk of recurrence, mortality, and recurrence patterns across the American Joint Committee on Cancer Eighth Edition (AJCC8) substages is needed. OBJECTIVE: To estimate stage-specific recurrence and melanoma-specific mortality rates, assess absolute stage-specific risks of recurrence and mortality, and describe stage-specific recurrence patterns, including conditional rates...
August 31, 2023: JAMA Dermatology
https://read.qxmd.com/read/37647073/mental-health-and-psychosocial-quality-of-life-burden-among-patients-with-vitiligo-findings-from-the-global-valiant-study
#18
JOURNAL ARTICLE
Kristen Bibeau, Khaled Ezzedine, John E Harris, Nanja van Geel, Pearl Grimes, Davinder Parsad, Mukta Tulpule, Jackie Gardner, Yan Valle, Gaone Tlhong Matewa, Christine LaFiura, Anouk Lindley, Haobo Ren, Iltefat H Hamzavi
IMPORTANCE: Patients with vitiligo often have impaired quality of life (QOL) and experience substantial psychosocial burden. OBJECTIVE: To explore the global association of vitiligo with QOL and mental health from the patient perspective. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study of the cross-sectional population-based Vitiligo and Life Impact Among International Communities (VALIANT) study was conducted from May 6, 2021, to June 21, 2021...
August 30, 2023: JAMA Dermatology
https://read.qxmd.com/read/37647058/risk-of-inflammatory-bowel-disease-in-patients-with-atopic-dermatitis
#19
JOURNAL ARTICLE
Zelma C Chiesa Fuxench, Joy Wan, Sonia Wang, Maha N Syed, Daniel B Shin, Katrina Abuabara, Joel M Gelfand
IMPORTANCE: Data on the association between atopic dermatitis (AD) and inflammatory bowel disease (IBD) are inconsistent. Few studies have examined the association of AD or AD severity with risk of ulcerative colitis (UC) and Crohn disease (CD) separately. OBJECTIVES: To examine the risk of new-onset IBD, UC, and CD in children and adults with AD. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study assessed patients with AD matched with up to 5 controls on age, practice, and index date...
August 30, 2023: JAMA Dermatology
https://read.qxmd.com/read/37647057/foscarnet-induced-penile-ulceration
#20
JOURNAL ARTICLE
Justin D Arnold, Janellen Smith
No abstract text is available yet for this article.
August 30, 2023: JAMA Dermatology
journal
journal
44126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.